AiCure

ViiV Healthcare

Janssen R&D, Viiv Healthcare collaborate on maintenance treatment for HIV

Friday, June 13, 2014 01:08 PM

Janssen R&D Ireland has entered into a collaboration with ViiV Healthcare to develop and commercialize a new, single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT) and ViiV's Integrase Inhibitor dolutegravir (marketed as TIVICAY) as the sole active ingredients for the maintenance treatment of people living with human immunodeficiency virus (HIV). The companies will further investigate development of this drug combination for pediatric use.

More... »


GlaxoSmithKline invests in Africa

Wednesday, April 2, 2014 01:54 PM

GlaxoSmithKline has announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth. GSK CEO Sir Andrew Wittyhasset out the company’s intent to partner with governments of African countries to help stimulate more research into chronic diseases, increase capacity by localizing medicines supply and strengthen healthcare infrastructure.

More... »


ideaPoint launches multi-sponsor portal

Thursday, January 2, 2014 10:35 AM

ideaPoint, a provider of partnering and collaboration systems for global enterprises, has announced the availability of a new portal providing a secure system for researchers to request access to anonymized, patient-level clinical trial data provided by sponsors (clinicalstudydatarequest.com). Study sponsors who have committed to provide data through the site currently include Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi and ViiV Healthcare.

More... »

Medicines Patent Pool collaborates with ViiV Healthcare

Friday, March 1, 2013 12:39 PM

The Medicines Patent Pool (MPP) has launched a collaboration with ViiV Healthcare—a joint venture of GlaxoSmithKline, Pfizer and Shionogi—to facilitate greater availability of critically needed medicines for children living with HIV.

More... »

Shionogi, ViiV Healthcare to commercialize and develop integrase inhibitor portfolio

Tuesday, October 30, 2012 11:19 AM

ViiV Healthcare, a global specialist HIV company based in the U.K., and Shionogi, a Japanese research-driven pharmaceutical company, have entered into an agreement substantially revising their integrase inhibitor relationship.

More... »

Siemens partners with ViiV Healthcare and Tocagen

Thursday, February 9, 2012 08:12 AM

Siemens Healthcare Diagnostics has formed two new companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen—marking a step for Siemens into the fast-growing segment of the in vitro diagnostics market.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs